Tony Xia ‘rejects £25m offer’ for Jordan Amavi


Dr Tony Xia, Owner of Aston Villa confirmed via Twitter that the club had rejected an offer of £25m for French left back Jordan Amavi. The 22-year-old Frenchman is in great demand with several high profile suitors. Marseille, Liverpool and Everton all doing their best to lure him back to his homeland.

As per Reports in France, Marseille are interested in signing the left-back as part of new owner Frank McCourt’s recruitment drive with La Provence. Moreover, there has been lots of speculations that sporting director Andoni Zubizarreta is in talks with the player’s representatives over a potential move.

Both Liverpool and Marseille are willing to buy Frenchman who joined Villa last year just to drop into the Champonship. But Xia insists that our players are not for sale. They can become a bigger player under Steve Bruce.Villa already paid around £9m to sign Amavi from Nice last summer and his current deal expires in 2020.

read more

Sean Parker Teams up to Give Humanity the World’s first Cancer Vaccine.


To defeat cancer, Tech Billionaire Sean Parker is starting $250 million project, which will focus on discovering highly personal tumor tags by using algorithms.


The Parker institute for Cancer Immunotherapy will work with more than 3 public and private pharmaceutical, biotech, cancer research nonprofits and academic institutions like the Broad Institute of MIT and Harvard, Caltech along with the Cancer Research Institute to bring an end to this disease. The partnership with the Cancer Research Institute will specifically focus on using bioinformatics to uncover these cancer markers.

Neoantigens is a genetic markers found only in tumors and are specific to individuals. It has created the latest buzz in cancer research, particularly in early cancer detection. They are tumor-unique amino acid tags that emerge as cells mutate into cancer. The encode immunologically active proteins that can help the immune system recognize the affected cell as foreign and signal the rest of the body’s infection-fighting army into the fray.


Each participants will study specific gene sequences from both cancerous and non-cancerous tissues, determining which ones are recognizable by t-cells. Once enough data is gathered, it can lead to producing more effective personalized neoantigen vaccines for cancer.


read more
1 2 3 7
Page 1 of 7